MedTrace Logo

Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer

NCT00868569 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-03-25

No results posted yet for this study

Summary

The purpose of this study is to investigate whether TAC plus FOLFOX4 or TACE plus folfox4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4 only.

Conditions

Interventions

PROCEDURE

TACE + folfox 4

tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml folfox4

PROCEDURE

TAC + folfox4

tac: oxaliplatin 100mg + fudr 1g + mmc 10mg folfox4

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • jianmin xu, MD, PHD · department of general surgery, zhongshan hospital, fudan university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868569 on ClinicalTrials.gov